GO:0140131 positive regulation of lymphocyte chemotaxis: Immune Cell Recruitment, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0140131 describes any process that increases the frequency, rate or extent of lymphocyte chemotaxis, the directed migration of T cells, B cells and NK cells along chemical gradients [2,5].
• Chemokine gradients, especially CXCL9, CXCL10, CXCL11 and CCL5, are central drivers of lymphocyte recruitment into tissues and tumors.
• Positive regulation of lymphocyte chemotaxis is required for effective antitumor immunity and is often suppressed in noninflamed tumors [2,7].
• Intracellular signaling molecules such as p66Shc and SLAMF1 can negatively or positively tune chemokine receptor signaling and lymphocyte chemotaxis [5,6].
• Tumor-associated macrophages and neutrophils can indirectly shape lymphocyte chemotaxis through chemokine reprogramming [3,4].
• CRISPR knockout, knock-in, point-mutation and overexpression models are powerful tools to dissect causal genes in this process.
Description
Positive regulation of lymphocyte chemotaxis (GO:0140131) is a biological process that increases the directed migration of lymphocytes along chemical gradients [2,5]. Lymphocytes, including CD8+ T cells, CD4+ T cells, B cells and NK cells, must navigate from blood and lymphoid organs into peripheral tissues and tumors to carry out immune surveillance and effector functions [2,3]. This process is essential for immune responses against pathogens and cancer, and its dysregulation contributes to autoimmunity, chronic inflammation and tumor immune evasion [2,7]. Understanding the molecular players that positively regulate lymphocyte chemotaxis is therefore a major goal in immunology and immuno-oncology [2,7]. Recent studies have shown that cooperation between constitutive and inducible chemokines, such as CXCL9, CXCL10 and CCL5, enables T cell engraftment and immune attack in solid tumors. Conversely, negative regulators such as p66Shc can dampen chemokine receptor signaling and B-cell chemotaxis, highlighting the importance of balanced positive regulation. This article integrates authoritative GO annotation with verified PubMed literature to provide a research-grade overview of GO:0140131, its mechanisms, key genes, disease relevance and experimental strategies.
positive regulation of lymphocyte chemotaxis At A Glance
| GO ID | GO:0140131 |
|---|---|
| GO term | positive regulation of lymphocyte chemotaxis |
| Ontology | biological_process |
| Synonym | none |
| Definition | Any process that activates or increases the frequency, rate or extent of lymphocyte chemotaxis. |
| Major function | Enhances directed migration of lymphocytes along chemokine gradients. |
| Related processes | Chemokine signaling, integrin activation, cytoskeletal rearrangement, immune cell recruitment. |
| Cell types involved | CD8+ T cells, CD4+ T cells, B cells, NK cells. |
| Disease relevance | Cancer immunotherapy, autoimmune diseases, chronic inflammation. |
What Is GO:0140131?
GO:0140131, positive regulation of lymphocyte chemotaxis, is defined as any process that activates or increases the frequency, rate or extent of lymphocyte chemotaxis. In other words, it encompasses molecular and cellular events that enhance the directed movement of lymphocytes toward chemoattractants such as chemokines. This term is a child of positive regulation of chemotaxis and is specific to lymphocytes, including T cells, B cells and NK cells. It does not describe the chemotactic movement itself, but rather the upstream or intracellular signals that amplify it.
Why Is positive regulation of lymphocyte chemotaxis Important in Cell Biology?
Positive regulation of lymphocyte chemotaxis is critical for mounting effective immune responses and for the success of cancer immunotherapy. Without efficient lymphocyte recruitment, tumors can evade immune attack, as seen in noninflamed tumor microenvironments where proinflammatory chemokines are suppressed. Conversely, excessive or misdirected lymphocyte chemotaxis contributes to autoimmune and inflammatory diseases such as Behçet's uveitis, where aberrant CD4+ naive T cell differentiation drives immune activation. Understanding the positive regulators of this process provides opportunities to enhance antitumor immunity and to dampen pathological inflammation.
• Enables CD8+ T cell infiltration into solid tumors, a prerequisite for immune checkpoint blockade efficacy.
• Supports T cell engraftment and immune attack in solid tumors through cooperation of constitutive and inducible chemokines.
• Is often suppressed in noninflamed tumors, leading to resistance to anti-PD-1/PD-L1 immunotherapy.
• Can be modulated by tumor-associated macrophages and neutrophils, which reprogram chemokine networks [3,4].
• Is negatively regulated by intracellular molecules such as p66Shc, which dampens B-cell chemotaxis.
• Is influenced by SLAMF1, which regulates chemotaxis and autophagy in chronic lymphocytic leukemia.
• Contributes to autoimmune pathology, as seen in Behçet's uveitis with aberrant CD4+ T cell differentiation.
• Is subject to circadian regulation by glucocorticoids, linking immunity to the circadian clock.
• Represents a therapeutic target for enhancing immunotherapy responses and controlling inflammation [2,7].
• Can be studied with CRISPR-based models to identify causal genes and pathways.
What Happens During positive regulation of lymphocyte chemotaxis?
Chemokine gradient formation and sensing
In simple terms: Cells release chemical signals that attract lymphocytes, and lymphocytes sense these signals.
Positive regulation of lymphocyte chemotaxis begins with the establishment of chemokine gradients. Constitutive and inducible chemokines such as CXCL9, CXCL10, CXCL11 and CCL5 cooperate to form gradients that guide T cells into tumors. Tumor-associated macrophages can be reprogrammed to support T-cell infiltration, as shown with CSF1/CSF1R inhibitor pexidartinib in sarcoma. Conversely, BCAT2 shapes a noninflamed tumor microenvironment by negatively regulating proinflammatory chemokines, thereby reducing lymphocyte recruitment. These gradients are sensed by chemokine receptors on lymphocytes, which initiate intracellular signaling.
Chemokine receptor signaling and intracellular amplification
In simple terms: Once the signal is received, molecules inside the lymphocyte amplify it to drive movement.
Chemokine receptor engagement activates intracellular signaling cascades that positively regulate lymphocyte chemotaxis. Negative regulators such as p66Shc can inhibit chemokine receptor signaling and B-cell chemotaxis, indicating that positive regulation involves overcoming such brakes. SLAMF1 regulates chemotaxis and autophagy in chronic lymphocytic leukemia cells, and its expression determines patient response, highlighting its role in modulating chemotactic responses. These signaling events lead to cytoskeletal rearrangements and integrin activation that propel cell movement.
Cytoskeletal rearrangement and cell polarization
In simple terms: The cell changes its shape and starts moving in the direction of the signal.
Positive regulation of lymphocyte chemotaxis requires dynamic reorganization of the actin cytoskeleton and cell polarization. Although specific cytoskeletal regulators are not detailed in the provided citations, the process is known to involve Rho GTPases and actin-binding proteins. The outcome is a polarized cell with a leading edge that extends toward the chemokine gradient. This step is essential for lymphocytes to physically migrate through tissues.
Transendothelial migration and tissue infiltration
In simple terms: Lymphocytes squeeze through blood vessel walls to reach the target tissue.
Once polarized, lymphocytes must cross the endothelium to enter tissues. Positive regulation of chemotaxis enhances this process, as evidenced by increased T-cell infiltration into tumors when chemokine gradients are optimized. In sarcoma, pexidartinib reprogrammed tumor-associated macrophages and stimulated T-cell infiltration, indirectly promoting lymphocyte chemotaxis. In lung cancer, CXCL5 impedes CD8+ T cell immunity by upregulating PD-L1 via PXN/AKT signaling and neutrophil chemotaxis, illustrating how other cells can negatively impact lymphocyte recruitment.
Integration with circadian and systemic signals
In simple terms: The body's clock and stress hormones can tune how many lymphocytes move.
Positive regulation of lymphocyte chemotaxis is not isolated; it is influenced by systemic signals. Glucocorticoids regulate the circadian rhythm of innate and adaptive immunity, which includes effects on lymphocyte trafficking. This integration ensures that lymphocyte recruitment peaks at appropriate times, optimizing immune surveillance and response. Dysregulation of these systemic cues may contribute to inflammatory diseases such as Behçet's uveitis, where aberrant CD4+ naive T cell differentiation drives immune activation.
Key Genes Involved in GO:0140131 positive regulation of lymphocyte chemotaxis
The following genes and proteins are experimentally implicated in positive regulation of lymphocyte chemotaxis or related chemotactic processes.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CXCL9 | Inducible chemokine that recruits CXCR3+ T cells | Mediates T cell engraftment in tumors |
| CXCL10 | Inducible chemokine that recruits CXCR3+ T cells | Cooperates with constitutive chemokines for T cell infiltration |
| CXCL11 | Inducible chemokine that recruits CXCR3+ T cells | Supports T cell recruitment in solid tumors |
| CCL5 | Constitutive chemokine that recruits CCR5+ T cells | Enables T cell engraftment and immune attack |
| CXCL5 | Neutrophil chemoattractant; indirectly impedes CD8+ T cell immunity | Upregulates PD-L1 via PXN/AKT signaling |
| p66Shc | Negative regulator of chemokine receptor signaling | Inhibits B-cell chemotaxis |
| SLAMF1 | Regulates chemotaxis and autophagy | Determines CLL patient response |
| BCAT2 | Negatively regulates proinflammatory chemokines | Shapes noninflamed tumor microenvironment |
| CSF1R | Macrophage receptor; its inhibition reprograms TAMs | Stimulates T-cell infiltration in sarcoma |
| PXN | Paxillin; involved in AKT signaling downstream of CXCL5 | Mediates PD-L1 upregulation in lung cancer |
| AKT | Kinase in signaling pathways | Phosphorylated in CXCL5-induced PD-L1 expression |
| PD-L1 | Immune checkpoint ligand | Upregulated by CXCL5, suppressing T cell immunity |
| CXCR3 | Receptor for CXCL9/10/11 | Mediates T cell chemotaxis toward inducible chemokines |
| CCR5 | Receptor for CCL5 | Mediates T cell chemotaxis toward constitutive chemokines |
| Glucocorticoid receptor | Mediates circadian regulation of immunity | Regulates lymphocyte trafficking |
| CD4 | Marker of helper T cells | Aberrant differentiation in Behçet's uveitis |
| CD8 | Marker of cytotoxic T cells | Key effector cells in antitumor immunity [2,4] |
How Is positive regulation of lymphocyte chemotaxis Regulated?
Positive regulation of lymphocyte chemotaxis is controlled at multiple levels. Intracellular negative regulators such as p66Shc can dampen chemokine receptor signaling, and their removal enhances chemotaxis. SLAMF1 modulates chemotaxis and autophagy, influencing CLL patient responses. Tumor-derived factors such as BCAT2 suppress proinflammatory chemokines, reducing lymphocyte recruitment. Conversely, inhibition of CSF1R with pexidartinib reprograms tumor-associated macrophages and stimulates T-cell infiltration, indirectly promoting chemotaxis. Systemic signals, including glucocorticoids, regulate the circadian rhythm of immunity and affect lymphocyte trafficking. These layers of regulation ensure that lymphocyte chemotaxis is appropriately timed and targeted.
positive regulation of lymphocyte chemotaxis and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| BCAT2 | Noninflamed tumor microenvironment, immunotherapy resistance | Knockout in tumor cells followed by chemokine profiling |
| CXCL5 | Lung cancer, CD8+ T cell suppression | Overexpression in lung cancer cell lines |
| SLAMF1 | Chronic lymphocytic leukemia | Knockout in CLL cell lines |
| p66Shc | B-cell chemotaxis regulation | Knockout in B cells |
| CSF1R | Sarcoma, T-cell infiltration | Inhibitor treatment in sarcoma models |
Cancer immunotherapy resistance
Noninflamed tumors often resist anti-PD-1/PD-L1 immunotherapy due to insufficient lymphocyte infiltration. BCAT2 shapes a noninflamed tumor microenvironment by negatively regulating proinflammatory chemokines, thereby reducing positive regulation of lymphocyte chemotaxis. In lung cancer, CXCL5 impedes CD8+ T cell immunity by upregulating PD-L1 via PXN/AKT signaling and neutrophil chemotaxis. Enhancing positive regulation of lymphocyte chemotaxis, for example by optimizing chemokine gradients, can overcome resistance and enable immune attack.
Chronic lymphocytic leukemia (CLL)
SLAMF1 regulation of chemotaxis and autophagy determines CLL patient response, linking positive regulation of lymphocyte chemotaxis to disease outcome. Dysregulated chemotaxis may promote leukemia cell survival and tissue infiltration. Targeting SLAMF1 or its downstream pathways could modulate chemotaxis and improve therapy.
Autoimmune and inflammatory diseases
Aberrant positive regulation of lymphocyte chemotaxis contributes to autoimmune pathology. In Behçet's uveitis, single-cell transcriptomic profiling revealed aberrant CD4+ naive T cell differentiation driving immune activation, which may involve enhanced chemotaxis. Modulating chemotaxis could reduce pathological lymphocyte recruitment.
Circadian and glucocorticoid-related immune modulation
Glucocorticoids regulate the circadian rhythm of innate and adaptive immunity, affecting lymphocyte trafficking. Disruption of this regulation may alter susceptibility to infections and inflammatory diseases. Understanding how glucocorticoids modulate positive regulation of lymphocyte chemotaxis could inform chronotherapy.
From positive regulation of lymphocyte chemotaxis-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X positively regulate lymphocyte chemotaxis? | CRISPR knockout in lymphocyte cell lines followed by chemotaxis assay |
| Does a point mutation in gene X alter chemokine receptor signaling? | CRISPR point mutation knock-in in primary T cells |
| Does overexpression of gene X enhance T cell infiltration in tumors? | CRISPR overexpression in CAR-T cells or tumor models |
| Does tagging gene X with a fluorescent marker affect its function? | CRISPR knock-in of GFP tag in lymphocytes |
| Does gene X regulate chemokine production in tumor cells? | CRISPR knockout in tumor cell lines followed by chemokine array |
| Can CRISPR library screening identify novel regulators of lymphocyte chemotaxis? | Genome-wide CRISPR knockout library in T cells under chemotaxis selection |
How to Study the positive regulation of lymphocyte chemotaxis Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Transwell chemotaxis assay | Directed migration of lymphocytes | Quantify chemotaxis after gene knockout |
| Microfluidic chemotaxis | Real-time cell migration dynamics | Study gradient sensing |
| Flow cytometry | Lymphocyte infiltration and phenotype | Assess T cell recruitment in tumors |
| Single-cell RNA-seq | Transcriptomic profiles of migrating cells | Identify chemotaxis-related gene signatures |
| CRISPR knockout screen | Genes required for chemotaxis | Discover novel positive regulators |
| Chemokine array | Chemokine secretion profiles | Measure tumor-derived chemokines |
| Immunohistochemistry | Tissue localization of lymphocytes | Evaluate tumor infiltration |
| Western blot | Signaling pathway activation | Assess AKT phosphorylation |
Chemotaxis assays
Transwell and microfluidic chemotaxis assays measure the directed migration of lymphocytes toward chemokine gradients. These assays are used to quantify positive regulation of lymphocyte chemotaxis in vitro, for example after CRISPR knockout of candidate genes [5,6].
Flow cytometry and immune profiling
Flow cytometry quantifies lymphocyte infiltration into tissues and tumors, providing in vivo evidence of positive regulation of chemotaxis. It can be combined with chemokine receptor staining to assess functional responses [2,3].
Single-cell transcriptomics
Single-cell RNA sequencing reveals heterogeneity in lymphocyte populations and their chemotactic programs. In Behçet's uveitis, this approach identified aberrant CD4+ naive T cell differentiation driving immune activation.
CRISPR screening and functional genomics
Genome-wide CRISPR knockout or activation screens can identify genes that positively or negatively regulate lymphocyte chemotaxis. These screens are powerful for discovering novel regulators and drug targets.
How CRISPR Can Be Used to Study GO:0140131 positive regulation of lymphocyte chemotaxis
Knockout
CRISPR knockout of candidate genes in lymphocyte cell lines or primary T cells can determine whether a gene is required for positive regulation of lymphocyte chemotaxis. For example, knocking out p66Shc, a negative regulator, would be expected to enhance chemotaxis. Knockout of BCAT2 in tumor cells could increase proinflammatory chemokines and lymphocyte recruitment.
Point Mutation
CRISPR point mutation knock-in allows precise modification of signaling residues. For instance, mutating phosphorylation sites in p66Shc or SLAMF1 could reveal their role in chemokine receptor signaling and chemotaxis [5,6]. This approach is ideal for studying structure-function relationships.
Knock-in
CRISPR knock-in of fluorescent tags or reporter genes into endogenous loci enables real-time tracking of chemotaxis-related proteins. Tagging CXCR3 or CCR5 with GFP would allow visualization of receptor dynamics during lymphocyte chemotaxis.
Overexpression
CRISPR overexpression of chemokines such as CXCL9, CXCL10 or CCL5 in tumor cells can enhance lymphocyte chemotaxis and improve antitumor immunity. Overexpression of SLAMF1 in CLL cells could modulate chemotaxis and autophagy.
How EDITGENE Supports positive regulation of lymphocyte chemotaxis Research
Researchers studying positive regulation of lymphocyte chemotaxis-related genes often need to determine whether a candidate gene is causally involved in enhancing or suppressing lymphocyte migration. EDITGENE provides a comprehensive suite of CRISPR services to enable such functional studies with high precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of lymphocyte chemotaxis research.
Frequently Asked Questions About positive regulation of lymphocyte chemotaxis
What is GO:0140131?
GO:0140131 is the Gene Ontology term for positive regulation of lymphocyte chemotaxis, defined as any process that activates or increases the frequency, rate or extent of lymphocyte chemotaxis.
What genes are involved in positive regulation of lymphocyte chemotaxis?
Key genes include chemokines such as CXCL9, CXCL10, CXCL11 and CCL5, as well as regulators like p66Shc, SLAMF1, BCAT2 and CSF1R [2,5,6,7,3].
How is lymphocyte chemotaxis regulated?
It is regulated by chemokine gradients, intracellular signaling molecules, and systemic factors such as glucocorticoids that influence circadian immunity [1,2,5].
Why is positive regulation of lymphocyte chemotaxis important in cancer?
It enables T cell infiltration into tumors, which is essential for effective immunotherapy. Suppression of this process leads to noninflamed tumors and resistance to anti-PD-1/PD-L1 therapy [2,7].
What diseases are associated with dysregulated lymphocyte chemotaxis?
Diseases include cancer immunotherapy resistance, chronic lymphocytic leukemia, autoimmune conditions like Behçet's uveitis, and inflammatory disorders [2,6,8].
How can CRISPR be used to study lymphocyte chemotaxis?
CRISPR knockout, knock-in, point mutation and overexpression models allow researchers to test the causal role of specific genes in lymphocyte chemotaxis [5,6,7].
What methods measure lymphocyte chemotaxis?
Transwell assays, microfluidic chemotaxis, flow cytometry, single-cell RNA-seq and CRISPR screens are commonly used [2,5,6,8].
What is the role of p66Shc in lymphocyte chemotaxis?
p66Shc negatively regulates chemokine receptor signaling and B-cell chemotaxis, so its inhibition enhances chemotaxis.
How does SLAMF1 affect chemotaxis?
SLAMF1 regulates chemotaxis and autophagy in chronic lymphocytic leukemia cells, and its expression determines patient response.
Can EDITGENE help with CRISPR models for chemotaxis research?
Yes, EDITGENE offers knockout, point mutation, knock-in, overexpression, library screening and bioinformatics services tailored to lymphocyte chemotaxis studies.
Conclusion
Positive regulation of lymphocyte chemotaxis (GO:0140131) is a fundamental biological process that governs the directed migration of lymphocytes into tissues and tumors. It is driven by chemokine gradients and modulated by intracellular regulators such as p66Shc and SLAMF1, as well as systemic signals like glucocorticoids [1,2,5,6]. Dysregulation of this process contributes to cancer immunotherapy resistance, autoimmune diseases and chronic inflammation [2,7,8]. CRISPR-based models are indispensable for dissecting the causal roles of specific genes in this process, and EDITGENE provides comprehensive services to support such research.
References
- 1. Shimba A et al.. 2020. Glucocorticoids Regulate Circadian Rhythm of Innate and Adaptive Immunity.. Front Immunol 11:2143 PMID: 33072078
- 2. Dangaj D et al.. 2019. Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors.. Cancer Cell 35(6):885-900.e10 PMID: 31185212
- 3. Fujiwara T et al.. 2021. CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment.. Mol Cancer Ther 20(8):1388-1399 PMID: 34088832
- 4. Sun D et al.. 2024. CXCL5 impedes CD8(+) T cell immunity by upregulating PD-L1 expression in lung cancer via PXN/AKT signaling phosphorylation and neutrophil chemotaxis.. J Exp Clin Cancer Res 43(1):202 PMID: 39034411
- 5. Patrussi L et al.. 2014. Negative regulation of chemokine receptor signaling and B-cell chemotaxis by p66Shc.. Cell Death Dis 5(2):e1068 PMID: 24556683
- 6. Bologna C et al.. 2016. SLAMF1 regulation of chemotaxis and autophagy determines CLL patient response.. J Clin Invest 126(1):181-94 PMID: 26619119
- 7. Cai Z et al.. 2023. BCAT2 Shapes a Noninflamed Tumor Microenvironment and Induces Resistance to Anti-PD-1/PD-L1 Immunotherapy by Negatively Regulating Proinflammatory Chemokines and Anticancer Immunity.. Adv Sci (Weinh) 10(8):e2207155 PMID: 36642843
- 8. Zhang L et al.. 2025. Single-cell transcriptomic profiling reveals aberrant CD4⁺ naive T cell differentiation driving immune activation in Behçet's uveitis.. J Transl Med 24(1):32 PMID: 41331613
